Table 1.

Patient demographics and characteristics.

Patient	Age category (years)	Sex	Duration of disease	Prior Tx	Race/Ethnicity	Histologic pattern in skina	Thoracic (Scadding stage)b	Heart	Extra-thoracic LN	Other
1	60–69	F	6 Yrs	M, P, I	White	Subcut	Yes (2)	Yes	No	None known
2	50–59	F	6 Yrs	H, M, P	Black/AA	Dermal (including LP)	Yes (1)	No	Yes	Ocular, nasal sinus
3	50–59	M	5 Yrs	H, M, P	Black/AA	Dermal	Yes (2)	No	Yes	spleen, nasal sinus
4	50–59	M	16 Yrs	M, P	Black/AA	Dermal (including LP)	Yes (1)	No	No	Nasal sinus
5	50–59	M	22 Yrs	M, P	White	Dermal and subcut (including LP and dactylitis)	Yes (2)	No	No	Ocular, nasal sinus
6	50–59	F	27 Yrs	M, P	Black/AA	Dermal (including LP)	Yes (2)	No	No	Laryngeal, nasal sinus
7	50–59	M	12 Yrs	M, P, I	Black/AA	Dermal and subcut	Yes (1)	No	Yes	None known
8	50–59	M	6 Yrs	M, A	White	Dermal	Yes (2)	No	Yes	None known
9	50–59	F	1 Yrs	M, P	White	Dermal	No (0)	No	No	None known
10	50–59	M	31 Yrs	M, P	Black/AA	Dermal and subcut (including LP)	Yes (2)	No	Yes	None known

Prior treatments (Tx) encompass all previously utilized therapies; in general trials of at least 3 months (often significantly longer) were attempted. In some cases, prior therapies were discontinued due to adverse effects. The therapeutic regimen for each patient at the beginning of the study is summarized in Fig. 1. Age reported as a range for patient privacy. Race reported according to recent guidelines⁵⁸, AA: African American. H: hydroxychloroquine, P: prednisone, M: methotrexate, I: infliximab, A: azathioprine. LP: signifies the presence of lupus pernio. ^aDermal: typical dermal-predominant pattern of inflammation histologically, subcut: subcutaneous predominant involvement (Darrier-Roussy pattern). ^bScadding stage: represents highest documented stage at any point in the patient’s history, stage I: adenopathy only, stage 2: adenopathy and parenchymal infiltration.